MDxHealth SA (NASDAQ:MDXH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

MDxHealth SA (NASDAQ:MDXH) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.6250.

A number of research firms recently issued reports on MDXH. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Lake Street Capital dropped their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research dropped their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Finally, William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th.

MDxHealth Stock Down 0.9%

Shares of NASDAQ MDXH opened at $0.75 on Monday. MDxHealth has a 52-week low of $0.68 and a 52-week high of $5.33. The firm has a fifty day moving average of $1.92 and a 200-day moving average of $2.94. The stock has a market capitalization of $37.27 million, a PE ratio of -1.16 and a beta of 1.37.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. The company had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. Equities research analysts expect that MDxHealth will post -0.6 EPS for the current fiscal year.

Institutional Trading of MDxHealth

A number of institutional investors have recently added to or reduced their stakes in MDXH. Kennedy Capital Management LLC purchased a new stake in shares of MDxHealth in the third quarter worth about $1,826,000. Marshall Wace LLP purchased a new stake in shares of MDxHealth in the fourth quarter worth about $609,000. Mink Brook Asset Management LLC purchased a new stake in shares of MDxHealth in the third quarter worth about $743,000. Panoramic Capital LLC purchased a new position in MDxHealth in the 3rd quarter worth approximately $721,000. Finally, FreeGulliver LLC boosted its holdings in MDxHealth by 104.7% in the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after acquiring an additional 129,348 shares during the period.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.